Addressing these key issues early can mean the difference between a smooth transition— or a disruptive and adversarial one.

The steady stream of merger and acquisition announcements in the lab/hospital space seems poised to continue through 2022 (at least.) Fortunately, the proliferation of these events has helped our team generate some helpful perspectives around some steps lab directors and LIS managers can take—to minimize the disruption to their essential functions while making sure their needs are accounted for within a tremendously complex process.